Fig. 1.

Changes from baseline in patient global disease activity (a), spinal pain (b), function (BASFI) (c), and stiffness (BASDAI questions 5 and 6) through week 52 (d). Values are LSM from MMRM. Week 1: PBO, Nx = 103; IXE Q4W, Nx = 95; IXE Q2W, Nx = 99. Week 2: PBO, Nx = 102; IXE Q4W, Nx = 96; IXE Q2W, Nx = 102. Weeks 4 and 8: PBO, Nx = 101; IXE Q4W, Nx = 96; IXE Q2W, Nx = 101. Weeks 12 and 16: PBO, Nx = 99; IXE Q4W, Nx = 96; IXE Q2W, Nx = 98. Week 20: PBO, Nx = 55; IXE Q4W, Nx = 68; IXE Q2W, Nx = 73. Week 24: PBO, Nx = 50; IXE Q4W, Nx = 64; IXE Q2W, Nx = 64. Week 28: PBO, Nx = 43; IXE Q4W, Nx = 63; IXE Q2W, Nx = 61. Week 32: PBO, Nx = 43; IXE Q4W, Nx = 59; IXE Q2W, Nx = 60. Week 36: PBO, Nx = 39; IXE Q4W, Nx = 56; IXE Q2W, Nx = 58. Week 44: PBO, Nx = 36; IXE Q4W, Nx = 54; IXE Q2W, Nx = 56. Week 52: PBO, Nx = 34; IXE Q4W, Nx = 53; IXE Q2W, Nx = 52. P values were from MMRM (treatment vs. placebo). *p < 0.05, ‡p < 0.01, †p < 0.001. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, IXE Q2W = 80-mg ixekizumab every 2 weeks, IXE Q4W 80-mg ixekizumab every 4 weeks, IXE Q2W 80-mg ixekizumab every 2 weeks, LSM least squares mean, MMRM mixed-effect model for repeated measures, Nx number of patients with non-missing values, PBO placebo